Abstract: A device for the removal of clot obstructing the flow of blood through an arterial vessel comprises an elongate member, a clot engaging element and a capture basket. The elongate member extends in use from a point adjacent a target treatment site interior of the patient to a point exterior of the patient. The capture basket comprises a frame and a net, and has an expanded and a collapsed configuration. The clot engaging element comprises a plurality of struts having an expanded and a collapsed configuration. The plurality of struts form a first section and a second section, the first section tapering outward and distally from the elongate member and connected to the second section. The second section comprises a plurality of cells defined by a plurality of struts and arranged around at least a portion of the circumference of an axis substantially parallel to that of the elongate member.

Abstract: A clot capture system for disengaging a clot from a vessel wall and removing the clot from the vessel, comprises a clot capture device for placement on a distal side of a clot. The clot capture device has a retracted delivery configuration and an expanded deployed configuration. The clot removal device has a proximal support frame, and a distal fibre net. The support frame has a retracted delivery configuration and an expanded deployed configuration. The proximal support frame in the expanded configuration defines a proximal inlet mouth for engaging a clot and a net for confining the clot. An elongate member facilitates capture and/or withdrawal of a clot from a vessel.

Abstract: A clot capture system for disengaging a clot 2001 from a vessel wall 2002 and removing the clot 2001 from the vessel 202, comprises a clot capture device 2140 for placement on a distal side of a clot 2001. The clot capture device 2140 has a retracted delivery configuration and an expanded deployed configuration. The clot removal device has a proximal support frame 2012, and a distal fibre net 2130. The support frame 2012 has a retracted delivery configuration and an expanded deployed configuration. The proximal support frame 2012 in the expanded configuration defines a proximal inlet mouth for engaging a clot 2001 and a net 2130 for confining the clot 2001. An elongate member facilitates capture and/or withdrawal of a clot 2001 from a vessel 2002. The system also comprises a clot debonding device 2091 for placement on a proximal side of a clot 2001.

Abstract: A tissue connecting device is provided. The device comprise an elongate delivery device having a lumen, a proximal end, and a distal end. The distal end is configured to engage tissue and advance said device into tissue. At least one anchor deliverable through a lumen of the elongate delivery device. The distal end of the device may be designed to engage tissue upon rotation of the device about its longitudinal axis.

Abstract: Compositions of matter comprise linked pluralities of mTOR-binding molecules, such as rapamycin. The compositions may be directly polymerized or may comprise rapamycin or other mTOR-binding molecules covalently or non-covalently attached to a backbone molecule. The compositions may be bound to vascular prostheses and other implantable devices in order to inhibit hyperplasia or for other therapeutic purposes.

Abstract: Compositions of matter comprise linked pluralities of mTOR-binding molecules, such as rapamycin. The compositions may be directly polymerized or may comprise rapamycin or other mTOR-binding molecules covalently or non-covalently attached to a backbone molecule. The compositions may be bound to vascular prostheses and other implantable devices in order to inhibit hyperplasia or for other therapeutic purposes.

Abstract: A method for delivering polymerized therapeutic agents and their compositions are disclosed. The various polymers take advantage of the functional domains found in a variety of therapeutic agents. The polymerized therapeutic agent compositions are prepared by covalently linking the agent to a biocompatible backbone either directly or through backbone conjugates/monomers. The polymerized therapeutic agent compositions of the invention have highly desirable properties, which make them particularly well suited for use in biological and biomedical applications.